Holen Sie sich die Stockscreener-App
1.44
2.70%
-0.04
Tiziana Life Sciences Ltd Aktie (TLSA) Neueste Nachrichten
Tiziana Life Sciences to Showcase Intranasal Foralumab at Neuroscience Innovation Forum During JPM Week - TipRanks
Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco - The Manila Times
Tiziana Life Sciences to present at 9th Annual Neurosciences Innovation Forum - Proactive financial news
Why Tiziana Life Sciences Ltd stock is rated strong buyQuarterly Portfolio Review & Safe Swing Trade Setup Alerts - ulpravda.ru
Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 7.4% – Still a Buy? - Defense World
Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 7.4%Still a Buy? - MarketBeat
Tiziana Life Sciences Files Annual Safety Report for Intranasal Foralumab with FDA - MarketScreener
Tiziana Life Sciences files annual safety report for intranasal foralumab - Yahoo Finance
Is Tiziana Life Sciences Ltd a good long term investmentSupport and Resistance Levels & Free Risk Assessment and Control - earlytimes.in
Tiziana Life Sciences submits annual safety report for intranasal foralumab to FDA - Proactive financial news
Tiziana Life Sciences Reports Positive Safety Profile for Intranasal Foralumab Following 37.4 Patient-Years of Exposure - Quiver Quantitative
Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA - The Manila Times
Small cap wrap: Tiziana Life Sciences, 374Water, First Phosphate... - Proactive financial news
Operating expenses (excl. COGS) of Tiziana Life Sciences Ltd. – GETTEX:0RP - TradingView — Track All Markets
Tiziana Life Sciences begins dosing in Phase 2 Alzheimer’s trialICYMI - Proactive financial news
Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman - The Manila Times
Tiziana Life Sciences Chair Boosts Stake to 36% with December Share Purchase - TipRanks
How buybacks impact Tiziana Life Sciences Ltd stock valueRecession Risk & Reliable Breakout Stock Forecasts - Улправда
Tiziana Life Sciences chairman increases stake to over 36% By Investing.com - Investing.com South Africa
Tiziana Life Sciences (TLSA) Chairman Expands Stake in the Compa - GuruFocus
Tiziana Life Sciences executive chairman increases stake - Proactive financial news
Why Tiziana Life Sciences Ltd stock is considered a top pickWeekly Stock Summary & Daily Risk Controlled Trade Plans - Bölüm Sonu Canavarı
Tiziana Life Sciences Executive Chairman Gabriele Cerrone Acquires Additional Shares, Increasing Ownership to 36.08% - Quiver Quantitative
Tiziana Life Sciences chairman increases stake to over 36% - Investing.com
Biotech founder lifts personal stake to 36% with latest share buy - Stock Titan
Can Tiziana Life Sciences Ltd stock maintain operating marginsShort Setup & Free Weekly Chart Analysis and Trade Guides - Улправда
Is Tiziana Life Sciences Ltd stock a buy on dipsIPO Watch & Safe Entry Zone Tips - DonanımHaber
Is Tiziana Life Sciences Ltd stock gaining market share2025 Market Overview & Daily Volume Surge Signals - Улправда
What risks investors should watch in Tiziana Life Sciences Ltd stockJuly 2025 Setups & Free Low Drawdown Momentum Trade Ideas - Улправда
How Tiziana Life Sciences Ltd stock performs during Fed tightening cyclesJuly 2025 Intraday Action & Stepwise Swing Trade Plans - Улправда
Tiziana Life Sciences Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Small cap wrap: Tiziana Life Sciences, NanoViricides, 1911 Gold, Protalix BioTherapeutics… - Proactive Investors
Tiziana Life Sciences doses first patient in Phase 2 Alzheimer’s clinical trial - Proactive financial news
Tiziana Life Sciences (NASDAQ: TLSA) marks Nasdaq bell with foralumab - Stock Titan
Tiziana Life Sciences to Ring the Closing Bell at Nasdaq - The Manila Times
Biotech behind nasal antibody for Alzheimer's to ring Nasdaq bell - Stock Titan
Tiziana Life Sciences doses first patient in Phase 2 Alzheimer's clinical trial - MarketScreener
TLSA Initiates Phase 2 Trial of Intranasal Foralumab for Alzheimer's Patients - GuruFocus
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial - The Manila Times
Tiziana Life Sciences doses first patient in mid-stage Alzheimer’s trial - Proactive Investors
Tiziana Life Sciences Doses First Patient with Intranasal Foralumab in Phase 2 Alzheimer’s Disease Trial - Quiver Quantitative
Tiziana Life Sciences (TLSA) begins Phase 2 intranasal foralumab AD trial - Stock Titan
New intranasal antibody trial targets neuroinflammation in early Alzheimer’s - Stock Titan
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer - The Manila Times
Tiziana Life Sciences CEO purchases 163,400 shares in open market By Investing.com - Investing.com Canada
Tiziana Life Sciences (TLSA) CEO boosts stake with 163,400-share purchase - Stock Titan
TLSA CEO Bolsters Stake with New Share Acquisition - GuruFocus
Tiziana Life Sciences CEO Increases Stake With Share Purchase - marketscreener.com
Tiziana Life Sciences CEO purchases 163,400 shares in open market - Investing.com
Ivor Elrifi Acquires Additional Shares of Tiziana Life Sciences Amidst Ongoing Clinical Development of Foralumab - Quiver Quantitative
Tiziana (NASDAQ: TLSA) CEO buys 163,400 shares in open market, now 357,848 - Stock Titan
Tiziana Life Sciences withdraws proposed public offering due to market conditions - Investing.com Nigeria
Tiziana Life Sciences withdraws proposed share offering - Proactive Investors
Tiziana CEO boosts stake with open-market share purchase - Proactive financial news
Tiziana Life Sciences Rescinds Proposed Public Offering - Nasdaq
TLSA Cancels Planned Public Offering Amid Market Conditions - GuruFocus
1.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):